Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a non-injectable, short-acting insulin with significantly improved efficacy over insulin aspart (Novo Nordisk's NovoRapid/NovoLog) would earn a 50 percent patient share in type 1 diabetes in the United States and a 58 percent patient share in Europe, according to surveyed U.S. and European endocrinologists.

The new report entitled Type 1 Diabetes: Opportunities Await Therapies That Offer Alternatives to Subcutaneous Injections of Insulins finds that interviewed endocrinologists are excited about Andromeda Biotech/DeveloGen's DiaPep 277, as it will potentially be the first safe disease modifying agent to reach the market for the treatment of type 1 diabetes. Although DiaPep 277 will not obviate the need for insulin injections, the maintenance of pancreatic beta cell function is anticipated to result in improved overall glycemic control for patients, together with reduced risk for hypoglycemia.

Basal-bolus insulin therapy using a regimen of insulin glargine (Sanofi-Aventis's Lantus) and a short-acting insulin analogue (Novo Nordisk's NovoRapid/NovoLog, Eli Lilly's Humalog) is Decision Resources' proprietary clinical gold standard for 2009. Following its anticipated approval for this indication in 2012, MannKind's Technosphere will replace the short-acting insulins as the new clinical gold standard for type 1 diabetes.

"In clinical trials, Technosphere has demonstrated a faster and more physiological action profile than insulin lispro or insulin aspart," said Decision Resources Analyst Caroline Gates. "Technosphere also ranks highly in the area of delivery according to survey data because it offers an alternative to the three-times-daily subcutaneous injections of short-acting insulin. The injection burden associated with the treatment of type 1 diabetes is very high and can involve up to five injections a day, so a reduction in the frequency of injections would be welcomed by both patients and physicians."

About the Report

Type 1 Diabetes: Opportunities Await Therapies That Offer Alternatives to Subcutaneous Injections of Insulins is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  Decision Resources                              Decision Resources, Inc.   Christopher Comfort                             Elizabeth Marshall   781-296-2597                                    781-296-2563   ccomfort@dresources.com                         emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Christopher Comfort of Decision Resources, +1-781-296-2597,
ccomfort@dresources.com; or Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Current and Emerging Therapies Have No Advantage Over Enbrel in Reducing the Signs and Symptoms of Rheumatoid Arthritis

View Now